Temozolomide-associated organizing pneumonitis

Fabien Maldonado, Andrew H. Limper, Kaiser G. Lim, Marie Christine Aubry

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

Temozolomide is an oral alkylating agent recently approved for the treatment of glioblastoma multiforme. It has a favorable side effect profile and is generally well tolerated. Although mild respiratory symptoms have been described, pulmonary toxicity that requires discontinuation of therapy is rare. To our knowledge, this is the first case of temozolomide-associated organizing pneumonitis.

Original languageEnglish (US)
Pages (from-to)771-773
Number of pages3
JournalMayo Clinic proceedings
Volume82
Issue number6
DOIs
StatePublished - Jun 2007

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this